The new EU-STAR clinical trial will enroll 40 patients at 5 centers in Germany and France, DFine reported. Researchers are looking to examine patients’ pain from 1 month following the procedure out to 6 months, as well as patients’ function, quality of life and reliance on pain medications.
DFine hopes to see more of the promising results that have turned up in earlier studies, in which patients were treated with STAR ablation prior to receiving vertebral augmentation to repair damage to the spine.
“Immediately following the procedure, the patient had a significant reduction in pain and increased activity level,” principal investigator Dr. Boris Joellenbeck said in prepared remarks. “We are excited about the many potential benefits of this therapeutic approach for our patients.”